Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Liraglutide Injection vs Victoza in Healthy Chinese Males
NCT05225974Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jul 2021
- Primary completion
- Jul 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration, Area under the plasma concentration versus time curve from time 0 to time t and 1 more. Started Jul 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05225974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225974.